tbuckley/cabot-search huggingface dataset:
Pattern and clinical significance of lymph node metastasis from hepatocellular carcinoma.
Authors: Byung min Lee, Jin-Young Choi, Jinsil Seong
Journal: Journal of Clinical Oncology (2022)

431 Background: We investigated clinical features and prognostic significance as well as the significance of local treatment on LN metastasis from HCC. Methods: The patients diagnosed of HCC with LN metastasis from 2001 to 2019 were evaluated. The HCC was diagnosed using image study and serum tumor marker based on Korean Liver Cancer Study Group guideline. The LN metastasis was diagnosed in accordance to diagnosis criteria in imaging study. The pattern of LN metastasis was evaluated based on imaging study and stratified by 3 groups: group A, regional LN metastasis group, group B, beyond regional intra-abdomen LN metastasis and group C, extra-abdomen LN metastasis group. Results: A total of 852 patients were included. The local treatment of either resection or RT were performed in 265 patients (31.1%). The OS between 3 groups was significantly different; the 1-year OS was 39.8%, 25.5% and 22.2% for group A, B and C, respectively ( p&lt;0.001). The local treatment group presented favorable features involving better liver function, controlled primary cancer and lesser extra-nodal metastasis than no local treatment group (CP-A: 72.5% vs. 54.2%, control of primary cancer: 44.9% vs. 8.7%, extra-nodal metastasis: 85.3% vs. 52.1%, p&lt;0.001). After propensity score matching (PSM), the features were well balanced between the two groups. The OS was significantly better in the local treatment group even after PSM (1-year OS: 51.8% vs. 26.6%, p&lt;0.001). Local treatment showed superior OS in both LN only metastasis and LN plus extra-nodal metastasis (62.3% vs. 31.6% vs. 45.0% vs. 23.4%, p&lt;0.001). In LN only metastasis patients, the dynamics of disease progression showed no difference between two groups ( p=0.651). Conclusions: This study showed that the survival and pattern of failure were significantly different depending on the location of LN metastasis. In patients with regional LN metastasis, active local treatment would enhance the survival of patients.
Journal of Applied Physiology, Bethesda
Journal: JAMA (1969)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Does the myocardium in human compensated ventricular hypertrophy revert to a dedifferentiated phenotype? Dirk W. Donker, Jos G. Maessen, Marc A. Vos, Paul G. A. Volders, Anton P. Gorgels, Leonard Hofstra, Jannie Ausma, Hans Duimel, Hein J. J. Wellens, Marcel Borgers. Department of Cardiology and Department of Cardiothoracic Surgery, Academic Hospital Maastricht, Maastricht, The Netherlands, Cardiovascular Research Institute Maastricht, Maastricht, The Netherlands
Journal: Journal of the American College of Cardiology (2001)
Target heart rate during dobutamine stress echocardiography: Where should we draw the line? Melda S. Dolan, Amr El-Shafei, Kamal Riad, Hassan Rajjoub, George Chahoud, Denice Sherriff, Wendy Watts, Michelle Bierig, Carrie Totta, Alan R. Maniet, Arthur J. Labovitz, Saint Louis University School of Medicine, St. Louis, MO
Journal: Journal of the American College of Cardiology (2001)
Queries and Minor Notes.
Journal: JAMA (1904)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
SGNTUC-019: Phase 2 basket study of tucatinib and trastuzumab in previously treated solid tumors with HER2 alterations—Biliary tract cancer cohort.
Authors: Tanios S. Bekaii-Saab, Jorge Ramos, Qianwen Tan, Yoshiaki Nakamura
Journal: Journal of Clinical Oncology (2022)

TPS489 Background: Tucatinib (TUC), a highly selective HER2-directed TKI approved in multiple regions for HER2+ metastatic breast cancer, is being investigated as a novel therapy for patients (pts) with metastatic colorectal cancer, gastric cancer, and other GI tumors. Preclinical and clinical data have shown HER2-targeted agents may improve clinical outcomes. In xenograft models of HER2+ and HER2-mutated tumors, dual targeting of HER2 with TUC + trastuzumab (Tras) showed superior activity to either agent alone (Kulukian 2020). Interim results from the MOUNTAINEER study have shown promising activity for TUC + Tras in HER2+ colorectal cancer. In 23 response-evaluable pts, an objective response rate (ORR) of 52% was observed with a median progression-free survival (PFS) of 8.1 months (mo) (Strickler 2019). The prognosis for pts with biliary tract cancers (BTCs) remain poor, and treatment options are limited. Given that approximately 12%-15% of BTC pts are HER2+, and 1%-8% have HER2 mutations, TUC + Tras warrants further evaluation in this patient population. The SGNTUC-019 basket study (NCT04579380) is evaluating TUC + Tras in pts with previously treated, locally advanced, unresectable or metastatic solid tumors including BTC that display HER2 overexpression/amplification or activating mutations. We describe the design of the BTC cohort. Methods: SGNTUC-019 is a multi-cohort, open-label, international Phase 2 study. Pts must be ≥18 years old; have an ECOG PS of ≤1; have adequate hepatic, hematological, renal, and cardiac functions; and have no previous exposure to HER2-directed therapy. BTC pts must have progressed on or after ≥1 previous line of treatment. The HER2+ BTC cohort will enroll 12 response-evaluable pts. If &gt;2 responses are observed, the cohort will be expanded to 30 pts. HER2-mutated BTC patients may also be enrolled in a 30 pts cohort for other HER2-mutated solid tumors. The primary objective is antitumor activity with confirmed ORR as the primary endpoint. Secondary efficacy endpoints include disease control rate, duration of response, PFS, and OS. For eligibility, HER2 alterations can be demonstrated by HER2 overexpression/amplification in tumor tissue by prior IHC/ISH, or by HER2 amplification/mutation in a prior or on-study NGS assay of ctDNA or prior tissue NGS assay. Pts will receive TUC 300 mg orally twice a day and Tras 8 mg/kg intravenously on Cycle 1 Day 1 then 6 mg/kg every 21 days from Cycle 2 Day 1. Disease assessments per RECIST 1.1 are every 6 weeks for the first 24 weeks, then every 12 weeks. Quality of life will be evaluated every 2 cycles using EQ-5D-5L. Sites are currently enrolling within the US, EU and Asia-Pacific. Clinical trial information: NCT04579380.
Phase II study of gemcitabine with oxaliplatin (GEMOX) in heavily treated patients with advanced hepatocellular carcinoma after failure of sorafenib treatment (PEACH).
Authors: Choong-kun Lee, Han Sang Kim, Hye Jin Choi
Journal: Journal of Clinical Oncology (2022)

456 Background: Recent advances in treatment of advanced hepatocellular carcinoma (HCC) includes novel immunotherapy and anti-angiogenic tyrosine kinases. However, there is no treatment option for the heavily treated HCC patients, and the role of cytotoxic chemotherapy regimens, such as oxaliplatin based doublets, are unknown. We aimed to investigate the antitumor activity of gemcitabine and oxaliplatin in advanced HCC patients who failed sorafenib treatment. Methods: This prospective single-arm, single-center phase II trial was conducted in Yonsei Cancer Center, Korea. Gemcitabine 1000mg/m 2 IV D1 and oxaliplatin 100mg/m 2 IV D1 were given every 2 weeks to Child Pugh Class A or B7 HCC patients who progressed after or cannot tolerate sorafenib treatment. Patients with HCC of &gt;60% liver occupation or portal vein invasion at the main portal branch (Vp4) were excluded. The primary endpoint was progression-free survival (PFS) rate at 6months and the secondary endpoints included PFS, overall survival (OS), objective response rate (ORR), disease control rate (DCR), safety profile, and exploratory molecular biomarker analysis. Results: Total of 32 patients were treated between May 2015 and July 2019 with median follow up of 10.2 months. Most of the patients were ECOG PS 1 (93.8%), B-viral (90.6%), and BCLC-C (96.9%). Patients had multiple distant metastatic sites including lung (81.2%) and lymph node (34.3%). Patients were heavily treated with 25% of patients treated as fourth-line and 18.7% of patients treated as fifth-line or later. The PFS rate at 6 months was 15.6%. Median PFS was 3.87 months and median OS was 10.5 months. 9.4% of the patients achieved partial response, and DCR was 65.6%. Median number of treatment cycles were 6 (range, 3 to 25). Treatment-related AE (≥G3) occurred in 15 patients (46.9%) including 5 patients (15.6%) with asthenia, 5 patients (15.6%) with sensory neuropathy, and 4 patients (12.5%) with thrombocytopenia. Conclusions: Gemcitabine and oxaliplatin for sorafenib failed, heavily treated advanced HCC were tolerable and showed modest efficacy. Although novel agents are currently adopted in clinics to treat advanced HCC, gemcitabine and oxaliplatin could be considered as later-line treatment option for heavily treated HCC patients. Exploratory molecular biomarker analysis results will be presented.
Soft Coal Miners' Health and Working Environment
Journal: JAMA (1942)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
2014 ACC/AHA Key Data Elements and Definitions for Cardiovascular Endpoint Events in Clinical Trials
Authors: Karen A. Hicks, James E. Tcheng, Biykem Bozkurt, Bernard R. Chaitman, Donald E. Cutlip, Andrew Farb, Gregg C. Fonarow, Jeffrey P. Jacobs, Michael R. Jaff, Judith H. Lichtman, Marian C. Limacher, Kenneth W. Mahaffey, Roxana Mehran, Steven E. Nissen, Eric E. Smith, Shari L. Targum
Journal: Journal of the American College of Cardiology (2014)
Нові можливості корекції печінкової енцефалопатії у хворих на цироз печінки
Authors: I.M. Gavrysh
Journal: GASTROENTEROLOGY (2014)

Обстежено 75 хворих на цироз печінки у поєднанні з дисбіозом кишечника, проведено оцінку клінічних проявів печінкової енцефалопатії, нейропсихометричних тестів, ступенів дисбіозу кишечника та включено до комплексного лікування препарат лакто- та біфідобактерій та гідрогель метилкремнієвої кислоти. Включення до комплексного лікування цих препаратів призводило до вірогідно кращої редукції суб’єктивних проявів цирозу печінки, суттєвої нормалізації мікробіоценозу кишечника, регресу печінкової енцефалопатії.
VACCINE IMMUNITY.
Journal: JAMA (1907)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Therapeutic angiogenesis by selective delivery of basic fibroblast growth factor in the anterior interventricular vein Mehrdad Rezaee, Neill A. Herity, Sidney Lo, Takeshi Suzuki, David P. Lee, Alan C. Yeung, Peter J. Fitzgerald, Andrew J. Carter, Paul G. Yock. Stanford University Medical Center, Stanford, CA
Journal: Journal of the American College of Cardiology (2001)
Can second-generation multitarget stool DNA panels reliably detect colorectal cancer and advanced precancerous lesions?
Authors: John B. Kisiel, Zubin D Gagrat, Martin Krockenberger, Abhik Bhattacharya, Bridget L Bourne, Christine M Leduc, Michael B Matter, Keith D Fourrier, David Edwards, Paul J. Limburg, Michael J. Domanico
Journal: Journal of Clinical Oncology (2022)

63 Background: Population-based colorectal cancer (CRC) screening can reduce mortality by detecting and removing advanced precancerous lesions (APL) and early-stage invasive disease. One guideline-included strategy is the multi-target stool DNA test (mt-sDNA), which combines detection of methylation DNA markers (MDMs), KRAS mutations, and fecal hemoglobin. Since the mt-sDNA pivotal study was conducted, novel biomarkers have been discovered. A panel of highly discriminant MDMs ( LASS4, LRRC4, PPP2R5C, and reference marker ZDHHC1) was identified through a blinded, case-control study of archival specimens. Here, we evaluated the performance of this novel mt-sDNA panel, combined with fecal hemoglobin, in archival stool samples weighted to early-stage CRC and prospectively collected APL, simulating a screening population. Methods: The verification study featured 777 samples—210 cases (112 CRC [49 stage I, 38 stage II, 17 stage III, and 8 stage IV] and 98 APL) and 567 controls (176 non-APL and 391 colonoscopy-negative)—from three trials (NCT01397747, NCT01260168, and NCT02503631). Median APL size was 12 mm (interquartile range: 10 mm to 15 mm), with 86.7% adenomas (n = 85) and 13.3% sessile serrated polyps (SSPs; n = 13). The average age was 65.5 years for cases (57% men) and 63.2 for controls (47% men). Samples were processed through homogenization, targeted MDM capture, bisulfite conversion, and MDM quantitation using Long‐probe Quantitative Amplified Signal (LQAS). Fecal hemoglobin was quantified using enzyme-linked immunosorbent assay (ELISA). Samples were split into stratified 75%/25% training-testing sets and model outcomes were cross-validated 1,000 times. Results: Mean performance from the cross-validation analysis is summarized in the table below. Overall sensitivity was 95.2% for CRC and 57.2% for APL, with specificities of 89.8% (no CRC/APL) and 92.4% (no neoplasia). Subgroup analyses showed high sensitivity for early-stage CRC, with 93.4% at stage I and 94.2% at stage II. By APL subtype, sensitivity was 82.9% for high-grade dysplasia, 73.4% for villous lesions, 49.8% for tubular lesions, and 30.2% for SSPs. Conclusions: These data support high sensitivity and specificity for a second-generation mt-sDNA panel. A multicenter pivotal trial evaluating the panel is underway (NCT04144738). [Table: see text]
Parovarian Cysts.
Authors: F. Shimonek
Journal: JAMA (1898)

Milwaukee, Wis., April 28, 1898. <h3>To the Editor:</h3> —I notice, in the last issue of theJournal, reference made in regard to Beyla's and Kelly's cases of enucleation of parovarian cysts without the removal of the tubes and ovaries, with the remark that those are the only cases ever reported. I have reported one case in the Transactions of the Wisconsin State Medical Society, 1897. The operation was done in July, 1895. Two parovarian cysts were removed; the right one was about the size of a small cocoanut. It was very easily enucleated. The top of the broad ligament was torn open with the finger and the cyst readily shelled out intact. The one in the left broad ligament was also enucleated, but with greater difficulty. Both were successfully removed without interfering with the tubes and ovaries. The patient made an uninterrupted recovery. Yours respectfully,
THE PUBLIC SERVICES.
Journal: JAMA (1893)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Abstract 372: CD16 Monocytes Stimulate Arteriogenesis to Salvage the Ischemic Limb
Authors: Ashish S Patel, Francesca E Ludwinski, Puja Kapoor, Paul R Jones, Alexander Kerr, Tamer El-Sayed, Prakash Saha, Oliver T Lyons, Alberto Smith, Bijan Modarai
Journal: Circulation Research (2017)

Introduction: Cell therapy using unselected mononuclear cell populations has had modest benefits in patients with critical limb ischemia (CLI). We hypothesized that tissue-remodeling monocytes, identified by their expression of CD16 (CD16+ Mo), may be a novel cellular therapy for CLI. Methods and Results: Flow cytometry showed that the proportion of circulating CD16+ Mo was greater in CLI patients (n=25) compared with matched controls (n=15, P&lt;0.0001). Removal of ischemia following revascularization or amputation resulted in a fall in CD16+ Mo to control levels (P&lt;0.05). CLI CD16+ Mo expressed higher levels of the adhesive proteins VLA, ICAM-1 and CD11c compared with controls (P&lt;0.05). Conditioned media from these cells contained higher levels of HB-EGF, PlGF, endoglin, VEGF-C and VEGF-D (P&lt;0.05) and induced greater endothelial cell tubule formation (P&lt;0.05) compared with CD16- Mo from the same patients (n=9). CD16+ Mo preferentially migrated towards ischemic muscle supernatants isolated from CLI patients (n=7, P&lt;0.02). CD16+ and CD16- Mo were isolated from 12 CLI patients and 1x10 6 cells injected into the adductor muscles of nude athymic mice following femoral artery excision. More ischemic hindlimbs were salvaged when treated with CD16+ compared with CD16- Mo (83% [10/12] vs 17% [2/12] limbs, P&lt;0.05) and this was associated with enhanced arteriogenesis (αSMA-stained vessels, P&lt;0.05). Conclusion: Circulating CD16+ Mo from CLI patients have increased expression of adhesion markers, are preferentially retained within ischemic muscle and promote robust arteriogenesis and limb salvage in experimental HLI. This monocyte subset may be an effective cellular therapy for CLI.
Advisory Board and Contents
Authors: Carsten Schradin, Lucas Garibaldi, Lisa Schulte, Diego Nabaes Jodar, Dulce Gomez Carella, Claire Kremen, Johannes Charlier, Eric Morgan, Ilias Kyriazakis, Vanessa Ezenwa, David Civitello, Aimée Classen, Brandon Barton, Daniel Becker, Maris Brenn-White, Sharon Deem, Susan Kutz, Matthew Malishev, Rachel Penczykowski, Daniel Preston, J Vannatta, Amanda Koltz Forum, Peng Jia, Shaoqing Dai, Tong Wu, Shujuan Yang, Angela Mcgaughran, Rebecca Laver, Ceridwen Fraser, Matthew Yates, Alison Derry, Melania Cristescu, Andrea Stephens, Jessica Miles, Margriet Ten Napel, Patrick Scheffmann, Sally Archibald, Göran Arnqvist, Ragan Callaway, Stephen Carpenter, James Clark, Rachel Collin, Isabelle Côté, Douglas Erwin, Tadashi Fukami, Stephen Jackson, Anna Liisa, Laine Lanfear, William Laurance, Baoguo Li, Akira Mori, Martin Nuñez, Samir Okasha, Sarah Otto, Natalia Harguindeguy, Nathalie Pettorelli, Rebecca Safran, William Sutherland, Maren Wellenreuther
Journal: Trends in Ecology & Evolution (2021)